HDAC9 and neoplasm: Many studies have used HDAC inhibitors to block lung fibrotic process and tumor growth, and SAHA, a nonselective HDAC Class I and II inhibitor, has been reported to have the ability to inhibit the differentiation of TGFβ1-induced myofibroblasts34–36.